Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease

education and communication strategies

Alessandro Armuzzi, Luisa Avedano, Kay Greveson, Taegyun Kang

Research output: Contribution to journalArticle

Abstract

The increasing prevalence of inflammatory bowel disease and the high costs associated with biological therapies suggest that biologicals with lower costs, but no compromise on efficacy and safety, should be considered when developing a treatment plan for inflammatory bowel disease. Biosimilars offer a more cost-effective alternative, and although the European Medicines Agency has approved the use of biosimilars for many indications, including inflammatory bowel disease, patients may be concerned about the safety and efficacy of these agents. The updated Nurses-European Crohn's and Colitis Organisation statements, published in March 2018, recommend that inflammatory bowel disease nurses facilitate patient choice of biological or biosimilar therapy. Nurses are pivotal in managing the challenges associated with patients transitioning to biosimilars. However, there is limited information available on how inflammatory bowel disease nurses can communicate the concept of biosimilars to patients and also on how best to support them before and during the switch from originators. This review article will focus on patients' concerns regarding biosimilars and describe considerations for nurses when supporting patients transitioning from originators to biosimilars. Through nurse-led patient education and the use of structured communication strategies as well as investment into managed switching programmes, patients will become more confident and adherent to their biosimilar therapy, and this may lead to overall reductions in healthcare expenditure for inflammatory bowel disease.

Original languageEnglish
JournalJournal of Crohn's & colitis
DOIs
Publication statusE-pub ahead of print - Oct 4 2018

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Nurses
Communication
Education
Safety
Costs and Cost Analysis
Biological Therapy
Cost of Illness
Patient Education
Health Expenditures

Cite this

@article{c94e9dc71b624b50bfd9333371d00f1e,
title = "Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease: education and communication strategies",
abstract = "The increasing prevalence of inflammatory bowel disease and the high costs associated with biological therapies suggest that biologicals with lower costs, but no compromise on efficacy and safety, should be considered when developing a treatment plan for inflammatory bowel disease. Biosimilars offer a more cost-effective alternative, and although the European Medicines Agency has approved the use of biosimilars for many indications, including inflammatory bowel disease, patients may be concerned about the safety and efficacy of these agents. The updated Nurses-European Crohn's and Colitis Organisation statements, published in March 2018, recommend that inflammatory bowel disease nurses facilitate patient choice of biological or biosimilar therapy. Nurses are pivotal in managing the challenges associated with patients transitioning to biosimilars. However, there is limited information available on how inflammatory bowel disease nurses can communicate the concept of biosimilars to patients and also on how best to support them before and during the switch from originators. This review article will focus on patients' concerns regarding biosimilars and describe considerations for nurses when supporting patients transitioning from originators to biosimilars. Through nurse-led patient education and the use of structured communication strategies as well as investment into managed switching programmes, patients will become more confident and adherent to their biosimilar therapy, and this may lead to overall reductions in healthcare expenditure for inflammatory bowel disease.",
author = "Alessandro Armuzzi and Luisa Avedano and Kay Greveson and Taegyun Kang",
year = "2018",
month = "10",
day = "4",
doi = "10.1093/ecco-jcc/jjy150",
language = "English",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease

T2 - education and communication strategies

AU - Armuzzi, Alessandro

AU - Avedano, Luisa

AU - Greveson, Kay

AU - Kang, Taegyun

PY - 2018/10/4

Y1 - 2018/10/4

N2 - The increasing prevalence of inflammatory bowel disease and the high costs associated with biological therapies suggest that biologicals with lower costs, but no compromise on efficacy and safety, should be considered when developing a treatment plan for inflammatory bowel disease. Biosimilars offer a more cost-effective alternative, and although the European Medicines Agency has approved the use of biosimilars for many indications, including inflammatory bowel disease, patients may be concerned about the safety and efficacy of these agents. The updated Nurses-European Crohn's and Colitis Organisation statements, published in March 2018, recommend that inflammatory bowel disease nurses facilitate patient choice of biological or biosimilar therapy. Nurses are pivotal in managing the challenges associated with patients transitioning to biosimilars. However, there is limited information available on how inflammatory bowel disease nurses can communicate the concept of biosimilars to patients and also on how best to support them before and during the switch from originators. This review article will focus on patients' concerns regarding biosimilars and describe considerations for nurses when supporting patients transitioning from originators to biosimilars. Through nurse-led patient education and the use of structured communication strategies as well as investment into managed switching programmes, patients will become more confident and adherent to their biosimilar therapy, and this may lead to overall reductions in healthcare expenditure for inflammatory bowel disease.

AB - The increasing prevalence of inflammatory bowel disease and the high costs associated with biological therapies suggest that biologicals with lower costs, but no compromise on efficacy and safety, should be considered when developing a treatment plan for inflammatory bowel disease. Biosimilars offer a more cost-effective alternative, and although the European Medicines Agency has approved the use of biosimilars for many indications, including inflammatory bowel disease, patients may be concerned about the safety and efficacy of these agents. The updated Nurses-European Crohn's and Colitis Organisation statements, published in March 2018, recommend that inflammatory bowel disease nurses facilitate patient choice of biological or biosimilar therapy. Nurses are pivotal in managing the challenges associated with patients transitioning to biosimilars. However, there is limited information available on how inflammatory bowel disease nurses can communicate the concept of biosimilars to patients and also on how best to support them before and during the switch from originators. This review article will focus on patients' concerns regarding biosimilars and describe considerations for nurses when supporting patients transitioning from originators to biosimilars. Through nurse-led patient education and the use of structured communication strategies as well as investment into managed switching programmes, patients will become more confident and adherent to their biosimilar therapy, and this may lead to overall reductions in healthcare expenditure for inflammatory bowel disease.

U2 - 10.1093/ecco-jcc/jjy150

DO - 10.1093/ecco-jcc/jjy150

M3 - Article

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

ER -